Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
17.06
+0.03 (0.15%)
Nov 21, 2024, 1:49 PM EST - Market open
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 37,851 employees as of December 31, 2023. The number of employees increased by 1,025 or 2.78% compared to the previous year.
Employees
37,851
Change (1Y)
1,025
Growth (1Y)
2.78%
Revenue / Employee
$443,106
Profits / Employee
-$25,336
Market Cap
19.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Labcorp Holdings | 67,000 |
Baxter International | 60,000 |
Quest Diagnostics | 48,000 |
Align Technology | 21,610 |
The Cooper Companies | 15,000 |
Illumina | 13,360 |
BeiGene | 10,600 |
Hologic | 6,990 |
TEVA News
- 2 days ago - Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 12 days ago - Teva to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 15 days ago - Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Teva Pharm CEO says will work productively with Trump administration - Reuters
- 15 days ago - Teva Pharmaceutical third-quarter profit, revenue top estimates - Reuters
- 15 days ago - Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS - GlobeNewsWire
- 19 days ago - Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition - GlobeNewsWire
- 19 days ago - Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) - GlobeNewsWire